Skip to main content
. 2018 Jul 30;8(7):e022291. doi: 10.1136/bmjopen-2018-022291

Table 4.

Mean and median times to complete resolution of attack symptoms

Treatment Mean time (SE) Median time (95% CI)
Time from treatment administration
 pdC1-INH, plasma derived C1-inhibitor (pdC1-INH) 14.10 (0.88) 7.5 (7 to 8.5)
 Icatibant 11.60 (1.04) 4 (3.5 to 5)
Time from onset of symptoms
 No treatment 50.5 (2.42) 47 (42 to 54)
 pdC1-INH 18.5 (1.09) 10 (9 to 10)
 Icatibant 15.3 (1.17) 7 (6 to 8)